HER2

Summary

Gene Symbol: HER2
Description: erb-b2 receptor tyrosine kinase 2
Alias: CD340, HER-2, HER-2/neu, HER2, MLN 19, NEU, NGL, TKR1, receptor tyrosine-protein kinase erbB-2, c-erb B2/neu protein, herstatin, human epidermal growth factor receptor 2, metastatic lymph node gene 19 protein, neuro/glioblastoma derived oncogene homolog, neuroblastoma/glioblastoma derived oncogene homolog, p185erbB2, proto-oncogene Neu, proto-oncogene c-ErbB-2, tyrosine kinase-type cell surface receptor HER2, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2, v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog
Species: human

Top Publications

  1. ncbi Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
    Hyun Soo Cho
    Department of Biophysics and Biophysical Chemistry, The Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, Maryland 21205, USA
    Nature 421:756-60. 2003
  2. ncbi Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016
    Wenle Xia
    Department of Discovery Medicine, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709 3398, USA
    Oncogene 23:646-53. 2004
  3. ncbi Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2
    Shao Chun Wang
    Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 6:251-61. 2004
  4. ncbi Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia
    Chang Gyu Hahn
    Cellular and Molecular Neuropathology Program, Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Nat Med 12:824-8. 2006
  5. ncbi Close association between HER-2 amplification and overexpression in human tumors of non-breast origin
    Coya Tapia
    Institute of Pathology, University of Basel, Basel, Switzerland
    Mod Pathol 20:192-8. 2007
  6. pmc Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, BC, Canada
    J Natl Cancer Inst 101:736-50. 2009
  7. doi RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
    Nicholas J Robert
    Virginia Cancer Specialists, US Oncology, Fairfax, VA, USA
    J Clin Oncol 29:1252-60. 2011
  8. ncbi Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    D J Slamon
    Department of Medicine, U C L A School of Medicine 90024
    Science 244:707-12. 1989
  9. doi Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
    Luca Gianni
    Oncologia Medica, San Raffaele Cancer Centre, Milan, Italy
    Lancet Oncol 13:25-32. 2012
  10. doi A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer
    Andrea Bertotti
    Laboratory of Molecular Pharmacology, Division of Surgical Oncology, Unit of Pathology, Institute for Cancer Research and Treatment, Torino, Italy
    Cancer Discov 1:508-23. 2011

Research Grants

  1. ERBB2 RECEPTOR SIGNALING AND BREAST CANCER METASTASIS
    Dihua Yu; Fiscal Year: 2002
  2. Mouse Models of ErbB-2 and Cyclin D1 in Prostate Cancer
    Christopher Albanese; Fiscal Year: 2002
  3. Coexpression of EGFRvlll/ErbB2 in Human Breast Cancer
    Careen Tang; Fiscal Year: 2005
  4. REBECCA SARA COOK; Fiscal Year: 2014
  5. A novel biotherapeutic for triple-negative breast cancer.
    Randolph C Elble; Fiscal Year: 2010
  6. Theranostic Nanomedicine for Breast Cancer Prevention and Image-Guided Therapy
    Prakash R Rai; Fiscal Year: 2011
  7. Prakash R Rai; Fiscal Year: 2014
  8. Jia Luo; Fiscal Year: 2016
  9. Lali K Medina-Kauwe; Fiscal Year: 2016
  10. Dai Horiuchi; Fiscal Year: 2014

Detail Information

Publications427 found, 100 shown here

  1. ncbi Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
    Hyun Soo Cho
    Department of Biophysics and Biophysical Chemistry, The Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, Maryland 21205, USA
    Nature 421:756-60. 2003
    b>HER2 (also known as Neu, ErbB2) is a member of the epidermal growth factor receptor (EGFR; also known as ErbB) family of receptor tyrosine kinases, which in humans includes HER1 (EGFR, ERBB1), HER2, HER3 (ERBB3) and HER4 (ERBB4)...
  2. ncbi Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016
    Wenle Xia
    Department of Discovery Medicine, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709 3398, USA
    Oncogene 23:646-53. 2004
    ..in breast cancer correlates with metastatic disease progression compared with the expression of full-length p185ErbB2. We now show that heregulin (HRG), but not EGF, stimulates p95ErbB2 phosphorylation in BT474 breast cancer cells...
  3. ncbi Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2
    Shao Chun Wang
    Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 6:251-61. 2004
    ..This study demonstrates the presence of ErbB-2 in the nucleus and identifies the function of ErbB-2 as a transcriptional regulator...
  4. ncbi Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia
    Chang Gyu Hahn
    Cellular and Molecular Neuropathology Program, Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Nat Med 12:824-8. 2006
    ..Therefore, these findings suggest that enhanced NRG1 signaling may contribute to NMDA hypofunction in schizophrenia...
  5. ncbi Close association between HER-2 amplification and overexpression in human tumors of non-breast origin
    Coya Tapia
    Institute of Pathology, University of Basel, Basel, Switzerland
    Mod Pathol 20:192-8. 2007
    ..Such tumor entities should be carefully evaluated for a possible utility of trastuzumab treatment...
  6. pmc Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, BC, Canada
    J Natl Cancer Inst 101:736-50. 2009
    ....
  7. doi RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
    Nicholas J Robert
    Virginia Cancer Specialists, US Oncology, Fairfax, VA, USA
    J Clin Oncol 29:1252-60. 2011
    ..and safety of bevacizumab (BV) when combined with several standard chemotherapy regimens versus those regimens alone for first-line treatment of patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.
  8. ncbi Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    D J Slamon
    Department of Medicine, U C L A School of Medicine 90024
    Science 244:707-12. 1989
    ..The HER-2/neu proto-oncogene is amplified in 25 to 30 percent of human primary breast cancers and this alteration is associated ..
  9. doi Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
    Luca Gianni
    Oncologia Medica, San Raffaele Cancer Centre, Milan, Italy
    Lancet Oncol 13:25-32. 2012
    Studies with pertuzumab, a novel anti-HER2 antibody, show improved efficacy when combined with the established HER2-directed antibody trastuzumab in breast cancer therapy...
  10. doi A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer
    Andrea Bertotti
    Laboratory of Molecular Pharmacology, Division of Surgical Oncology, Unit of Pathology, Institute for Cancer Research and Treatment, Torino, Italy
    Cancer Discov 1:508-23. 2011
    ..Genotype-response correlations indicated HER2 amplification specifically in a subset of cetuximab-resistant, KRAS/NRAS/BRAF/PIK3CA wild-type cases...
  11. pmc Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients
    J D Barros-Silva
    Department of Genetics, Portuguese Oncology Institute, Porto, Portugal
    Br J Cancer 100:487-93. 2009
    ....
  12. doi HER-2 amplification is highly homogenous in gastric cancer
    Andreas H Marx
    Institute of Pathology, University Medical Center Hamburg Eppendorf, Germany
    Hum Pathol 40:769-77. 2009
    ..The high level of HER-2 amplification in combination with the homogeneity of its expression in primary and metastatic tumors argues for a possible therapeutic utility of trastuzumab in HER-2-amplified gastric adenocarcinomas...
  13. pmc The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
    Thomas Holbro
    Friedrich Miescher Institute, P O Box 2543, 4002 Basel, Switzerland
    Proc Natl Acad Sci U S A 100:8933-8. 2003
    ..Furthermore, we identify ErbB3's role, which is to couple active ErbB2 to the phosphatidylinositol 3-kinase/protein kinase B pathway. Thus, the ErbB2/ErbB3 dimer functions as an oncogenic unit to drive breast tumor cell proliferation...
  14. ncbi Lung cancer: intragenic ERBB2 kinase mutations in tumours
    Philip Stephens
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
    Nature 431:525-6. 2004
    ..We have sequenced the gene encoding the transmembrane protein tyrosine kinase ERBB2 (also known as HER2 or Neu) from 120 primary lung tumours and identified 4% that have mutations within the kinase domain; in the ..
  15. pmc Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer
    Jamie K Miller
    School of Medicine, Davis Cancer Center, University of California at Davis, Sacramento, California 95817, USA
    Cancer Res 68:8286-94. 2008
    ..Moreover, our observations point to the existence of a feed-forward regulatory loop in breast tumor cells where aberrant ErbB2 signaling suppresses LRIG1 protein levels, which in turn contributes to ErbB2 overexpression...
  16. pmc LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation
    Gal Gur
    Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel
    EMBO J 23:3270-81. 2004
    ..We conclude that LRIG1 evolved in mammals as a feedback negative attenuator of signaling by receptor tyrosine kinases...
  17. pmc Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies
    Nadège Gaborit
    IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM, U896, Université Montpellier1, CRLC Val d Aurelle Paul Lamarque, Montpellier, France
    J Biol Chem 286:11337-45. 2011
    In oncology, simultaneous inhibition of epidermal growth factor receptor (EGFR) and HER2 by monoclonal antibodies (mAbs) is an efficient therapeutic strategy but the underlying mechanisms are not fully understood...
  18. doi Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays
    Kab Choong Kim
    Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
    Ann Surg Oncol 18:2833-40. 2011
    Recent advances in molecular targeted therapy have identified HER2 as an important target for anti-cancer therapy in gastric cancer (GC)...
  19. ncbi Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions
    Bolin Liu
    Department of Pathology, University of Colorado Denver School of Medicine, Aurora, CO, USA
    Cell Cycle 10:2959-66. 2011
    ..This action appears to be independent of mTOR signaling. Our findings provide a rationale to study the effects of metformin on patients with erbB2 positive tumors treated with trastuzumab, with or without resistance...
  20. pmc MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells
    Chin Tung Chen
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Mol Cancer Ther 11:660-9. 2012
    b>HER2 amplification is found in more than 15% of gastric cancers and is associated with poor clinical outcome...
  21. ncbi Memo mediates ErbB2-driven cell motility
    Romina Marone
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    Nat Cell Biol 6:515-22. 2004
    ..a set of signalling molecules, including MAPK, phosphatidylinositol-3-OH kinase (PI(3)K) and Src, is required for Neu/ErbB2-dependent lamellipodia formation and for motility of breast carcinoma cells...
  22. doi Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance
    Guan Zhen Yu
    Department of Oncology, Changzheng Hospital, 200070 Shanghai, People s Republic of China
    J Cancer Res Clin Oncol 135:1331-9. 2009
    Growth factor receptor-bound 2 (Grb2)-mediated HER2 signaling is thought to play a critical role in gastric cancer development, progression and metastasis. However, little is known about their expression in gastric cancer...
  23. pmc ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner
    M A Olayioye
    Friedrich Miescher Institute, CH 4002 Basel, Switzerland
    Mol Cell Biol 18:5042-51. 1998
    ..This model system allowed the comparison of EGF-activated ErbB-1 with ErbB-1 activated by Neu differentiation factor (NDF)-induced heterodimerization with ErbB-4...
  24. ncbi NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer
    Miguel A Molina
    Laboratory of Oncology Research, Medical Oncology Service, Vall d Hebron Hospital, 08035 Barcelona, Spain
    Clin Cancer Res 8:347-53. 2002
    ..P95HER-2 has potentially enhanced signaling activity, but its expression and role in human breast cancer is poorly characterized...
  25. ncbi Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signaling
    J H Zhu
    Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Oncogene 27:2525-31. 2008
    Deregulated Her2/ErbB2 receptor tyrosine kinase drives tumorigenesis and tumor progression in a variety of human tissues. Her2 transmits oncogenic signals through phosphorylation of its cytosolic domain...
  26. doi Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers
    Andreas H Marx
    Institute for Pathology, Hubertus Wald Tumorzentrum University Cancer Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
    Hum Pathol 41:1577-85. 2010
    ..Heterogeneity of amplification may limit the utility of anti- HER-2 therapy in some of these tumors and therefore, adequate clinical trials are needed to further evaluate this approach...
  27. doi ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression
    Bo Rafn
    Unit of Cell Death and Metabolism and Centre for Genotoxic Stress Research, Danish Cancer Society Research Center, Strandboulevarden 49, Copenhagen 2100, Denmark
    Mol Cell 45:764-76. 2012
    ..This work provides a model system for ErbB2-induced breast cancer cell invasiveness, reveals a signaling network that is crucial for invasion in vitro, and defines a specific role and targets for the identified serine-threonine kinases...
  28. doi Clinical significance of intratumoral HER2 heterogeneity in gastric cancer
    Hee Eun Lee
    Department of Pathology, Seoul National University Hospital, Seoul, South Korea
    Eur J Cancer 49:1448-57. 2013
    To evaluate the clinical significance of intratumoral HER2 heterogeneity in gastric cancer (GC).
  29. doi Frequency of HER-2 positivity in rectal cancer and prognosis
    Lena Christin Conradi
    Department of General and Visceral Surgery, University Medical Center, Gottingen, Germany
    Am J Surg Pathol 37:522-31. 2013
    ..7%) of rectal cancer patients. For the development of innovative new therapies, HER-2 may represent a promising target and should be further assessed within prospective clinical trials...
  30. doi MiR-199b-5p targets HER2 in breast cancer cells
    Chen Fang
    Department of Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai 200433, China
    J Cell Biochem 114:1457-63. 2013
    b>HER2 (ErbB2) has been reported to be overexpressed in 20-30% of breast cancer and confers poor survival because of high proliferation and metastasis rates...
  31. ncbi Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients
    Gottfried E Konecny
    Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1678, USA
    Clin Cancer Res 10:1706-16. 2004
    Activation or overexpression of HER-2/neu is associated with up-regulation of vascular endothelial growth factor (VEGF) in human breast cancer cells in vitro...
  32. doi Memo is a cofilin-interacting protein that influences PLCgamma1 and cofilin activities, and is essential for maintaining directionality during ErbB2-induced tumor-cell migration
    Maria Meira
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    J Cell Sci 122:787-97. 2009
    ..In summary, these data indicate that Memo also regulates actin dynamics by interacting with cofilin and enhancing its function...
  33. pmc HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005
    Katri Köninki
    Institute of Medical Technology, University of Tampere, Tampere, Finland
    Breast Cancer Res 11:R37. 2009
    ..A decrease in the proportion of HER-2-positive breast cancer has been suspected, but no data on the incidence trends at population level have been reported...
  34. ncbi HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy
    Alfredo Santinelli
    Department of Neuroscience, Polytechnic University of Marche Region, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I G M Lancisi G Salesi, Via Conca 71, I 60020 Torrette di Ancona, Ancona, Italy
    Int J Cancer 122:999-1004. 2008
    ..This procedure could be also suggested in the patients that are metastatic at the time of diagnosis...
  35. doi HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer
    Julie E Lang
    Department of Surgical Oncology, MD Anderson Cancer Center, Advanced Research Center for Microscopic Disease, The University of Texas, Houston, TX 77030, USA
    Breast Cancer Res Treat 113:501-7. 2009
    ..We hypothesized that primary tumor characteristics would predict the likelihood of identifying CTCs in patients with operable breast cancer...
  36. pmc A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma
    K Semba
    Proc Natl Acad Sci U S A 82:6497-501. 1985
    ..Southern blot analysis showed close similarity of the restriction patterns of the rat c-erbB-2 gene and the rat neu oncogene, suggesting possible involvement of c-erbB-2 in human cancer...
  37. pmc Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment
    Zachary T Schafer
    Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 461:109-13. 2009
    ..These results show both the importance of matrix attachment in regulating metabolic activity and an unanticipated mechanism for cell survival in altered matrix environments by antioxidant restoration of ATP generation...
  38. pmc Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma
    Min A Kim
    Department of Pathology, Seoul National University College of Medicine, Seoul, Korea
    Histopathology 59:822-31. 2011
    To determine the extent of HER2 homogeneity/heterogeneity in primary versus metastatic gastric carcinoma (GC).
  39. doi PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
    J D Jensen
    Department of Oncology, Odense University Hospital, and Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
    Ann Oncol 23:2034-42. 2012
    ..This study was conducted to determine the frequency of PIK3CA mutations and human epidermal growth factor receptor-2 (HER2) phosphorylation status (pHER2-Tyr1221/1222) and if PIK3CA, phosphatase and tensin homolog (PTEN), or pHER2 has an ..
  40. ncbi Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin
    Sergio Anastasi
    Laboratory of Immunology, Regina Elena Cancer Institute, Via delle Messi d oro, 156 158, 00158, Rome, Italy
    Oncogene 24:4540-8. 2005
    ..Thus, loss of RALT expression cooperates with ERBB2 gene amplification to drive full oncogenic signalling by the ErbB-2 receptor. Moreover, loss of RALT signalling may adversely affect tumor responses to ErbB-2-targeting agents...
  41. doi Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial
    Isabell Witzel
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany
    Breast Cancer Res Treat 123:437-45. 2010
    ..Serum markers could help to monitor and optimize such treatment strategies. We investigated human epidermal growth factor receptor 2 serum (sHER2) levels in 175 breast cancer patients participating in the GeparQuattro trial...
  42. ncbi Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer
    Wolfgang J Kostler
    Department of Medicine I, University Hospital of Vienna, Austria
    Clin Cancer Res 10:1618-24. 2004
    The present pilot study was performed to elucidate whether early changes in serum Her-2/neu extracellular domain (ECD) levels during trastuzumab-based treatment would predict the clinical course of disease in patients with metastatic ..
  43. ncbi Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin
    E G Mimnaugh
    Clinical Pharmacology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 271:22796-801. 1996
    ....
  44. pmc HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion
    H Korkaya
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
    Oncogene 27:6120-30. 2008
    ..The HER2 gene is amplified in 20-30% of human breast cancers and has been implicated in mammary tumorigenesis as well as in ..
  45. pmc Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein
    Kathleen Aertgeerts
    Takeda San Diego Inc, 10410 Science Center Drive, San Diego, California 92121, USA
    J Biol Chem 286:18756-65. 2011
    Aberrant signaling of ErbB family members human epidermal growth factor 2 (HER2) and epidermal growth factor receptor (EGFR) is implicated in many human cancers, and HER2 expression is predictive of human disease recurrence and prognosis...
  46. ncbi Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction
    Min A Kim
    Department of Pathology, Seoul National University College of Medicine, Seoul 110 799, Korea
    Hum Pathol 38:1386-93. 2007
    ..9% specificity using FISH results as the standard. Measurements of HER-2 expression by FISH and real-time q-PCR and of HER-2 protein by IHC were found to be highly concordant at determining HER-2 status in gastric carcinoma...
  47. ncbi Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins
    D Dankort
    Institute for Molecular Biology and Biotechnology, Departments of Biology and Pathology, McMaster University, Hamilton, Ontario L8S 4K1, Canada
    J Biol Chem 276:38921-8. 2001
    Amplification of the type I receptor tyrosine kinase ErbB-2 (HER2/Neu) is observed in 20-30% of human mammary carcinomas, correlating with a poor clinical prognosis...
  48. ncbi ErbB-2 activates Stat3 alpha in a Src- and JAK2-dependent manner
    Zhiyong Ren
    Department of Neurosurgery, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Biol Chem 277:38486-93. 2002
    ....
  49. pmc Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarity
    A V Lucs
    Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA
    Oncogene 29:174-87. 2010
    ..Furthermore, we identify a novel function for Shc as a regulator of apoptosis and drug resistance in human mammary epithelial cells transformed by ErbB2...
  50. doi NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity
    Sarala Manandhar
    College of Pharmacy, Yeungnam University, Gyeongsangbuk do 712 749, Republic of Korea
    Free Radic Biol Med 52:1773-85. 2012
    ....
  51. pmc Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications
    Brent N Rexer
    Departments of Medicine and Cancer Biology, Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37212, USA
    Crit Rev Oncog 17:1-16. 2012
    Approximately 25% of human breast cancers overexpress the HER2 (ErbB2) proto-oncogene, which confers a more aggressive tumor phenotype and associates with a poor prognosis in patients with this disease...
  52. ncbi ErbB2 degradation mediated by the co-chaperone protein CHIP
    Pengcheng Zhou
    Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 278:13829-37. 2003
    ....
  53. pmc Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells
    Javier A Menendez
    Department of Medicine, Evanston Northwestern Healthcare, 1001 University Place, Evanston, IL 60201, USA
    Proc Natl Acad Sci U S A 101:10715-20. 2004
    ..Here, we have identified a molecular link between FAS and HER2 (erbB-2) oncogene, a marker for poor prognosis that is overexpressed in 30% of breast and ovarian cancers...
  54. pmc The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors
    Abdelkader Allouche
    Department of Pathology, GIGA Research, CRCE, University of Liege and CHU of Liege, B23, Avenue de l Hopital, 3, 4000 Liege, Belgium
    Breast Cancer Res 10:R9. 2008
    ..In this report, we examined the relationships between ERBB2, AP-2alpha, and YY1 both in breast cancer tissue specimens and in a mammary cancer cell line...
  55. pmc Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6
    Gary K Scott
    Buck Institute for Age Research, Novato, CA 94945, USA
    Mol Cancer Res 6:1250-8. 2008
    ....
  56. pmc Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion
    Tzu Hsuan Huang
    Department of Microbiology and Immunology, University of California, San Francisco, California 94143, USA
    J Biol Chem 284:18515-24. 2009
    The cell surface receptor tyrosine kinase HER2/neu enhances tumor metastasis...
  57. pmc ErbB2 receptor controls microtubule capture by recruiting ACF7 to the plasma membrane of migrating cells
    Kossay Zaoui
    Centre de Recherche en Cancerologie de Marseille, Institut National de la Santé et de la Recherche Médicale U891, 13009 Marseille, France
    Proc Natl Acad Sci U S A 107:18517-22. 2010
    ..By defining the signaling pathway by which ErbB2 allows MT capture and stabilization at the cell leading edge, we provide insights into the mechanism underlying cell motility and steering...
  58. doi In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer
    Melanie Spears
    Edinburgh Breakthrough Breast Cancer Unit, Edinburgh Cancer Research Centre, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, UK
    Breast Cancer Res Treat 132:463-70. 2012
    b>HER2 overexpression/amplification is linked with poor prognosis in early breast cancer...
  59. doi In situ analysis of HER2 mRNA in gastric carcinoma: comparison with fluorescence in situ hybridization, dual-color silver in situ hybridization, and immunohistochemistry
    Min A Kim
    Department of Pathology, Seoul National University College of Medicine, Seoul 110 799, Republic of Korea
    Hum Pathol 44:487-94. 2013
    The importance of anti-HER2 therapy has focused attention on the ability of clinical assays to correctly assign HER2 amplification status...
  60. pmc Receptor tyrosine kinase ErbB2 translocates into mitochondria and regulates cellular metabolism
    Yan Ding
    Mitchell Cancer Institute, University of South Alabama, MCI 3016, 1600 Spring Hill Avenue, Mobile, Alabama 36604, USA
    Nat Commun 3:1271. 2012
    ..Our study provides a novel perspective on the metabolic regulatory function of ErbB2 and reveals that mtErbB2 has an important role in the regulation of cellular metabolism and cancer cell resistance to therapeutics...
  61. pmc HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy
    Jessica N McAlpine
    Department of Gynaecology and Obstetrics, University of British Columbia, Vancouver, BC, Canada
    BMC Cancer 9:433. 2009
    ..We investigated HER2 expression and amplification, and the potential for trastuzumab therapy in this histologic subtype of ovarian cancer...
  62. doi Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH)
    Shinichiro Kiyose
    Department of Tumor Pathology, Hamamatsu University School of Medicine, Japan
    Pathol Int 62:728-34. 2012
    The chromogenic in situ hybridization (CISH) assay, designed to detect the amplification of the HER2 gene in formalin-fixed, paraffin-embedded (FFPE) breast cancer (BC) and gastric cancer (GC) tissue specimens, was evaluated in 125 FFPE ..
  63. ncbi ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas
    Joyce A Schroeder
    Tumor Biology Program and Department of Biochemistry and Molecular Biology, Mayo Medical Graduate School, Mayo Clinic Scottsdale, Scottsdale, Arizona 85259, USA
    J Biol Chem 277:22692-8. 2002
    ..carcinoma, we have identified an unvarying association between beta-catenin and epidermal growth factor receptor/c-Neu (ErbB1/ErbB2) heterodimers in mammary gland tumors, indicating a requirement for ErbB signaling in Wnt-mediated ..
  64. doi A negative feedback regulatory loop associates the tyrosine kinase receptor ERBB2 and the transcription factor GATA4 in breast cancer cells
    Guoqiang Hua
    Universite de la Mediterranee, Institut Paoli Calmettes, Centre de Cancérologie de Marseille, Marseille, France
    Mol Cancer Res 7:402-14. 2009
    ..We propose that the negative feedback loop linking ERBB2 and GATA4 plays a role in the transcriptional dysregulation of ERBB2 gene expression in breast cancer...
  65. doi Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma
    Na Zhan
    Department of Pathology, Renmin Hospital of Wuhan University, 430060 Wuhan, Hubei, China
    Med Oncol 29:933-40. 2012
    The HER2 gene, which is located on chromosomes 17, is a therapeutic target for cancer. Amplification of HER2 has been described in several tumor types...
  66. pmc YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification
    A H Davies
    Laboratory of Oncogenomic Research, Departments of Pediatrics and Experimental Medicine, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada
    Oncogene 30:3649-60. 2011
    ..As malignancy further progressed, we identified a subset of cells harboring HER2 amplification...
  67. doi Relation between transforming growth factor-β1 expression, its receptor and clinicopathological factors and survival in HER2-negative gastric cancers
    Julian Ananiev
    Department of General and Clinical Pathology and Forensic Medicine, Medical Faculty, Trakia University, Stara Zagora, Bulgaria
    Wien Klin Wochenschr 123:668-73. 2011
    ..of transforming growth factor - β1 (TGF-β1) and transforming growth factor - β1 receptor II (TGF-β1RII) in HER2/neu negative gastric carcinomas and to explore the correlations, the clinicopathological characteristics and ..
  68. pmc Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas
    C L Arteaga
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232
    Proc Natl Acad Sci U S A 88:10435-9. 1991
    ....
  69. pmc miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer
    Michael R Epis
    Laboratory for Cancer Medicine, University of Western Australia Center for Medical Research, Western Australian Institute for Medical Research, Perth, Western Australia 6000, Australia
    J Biol Chem 284:24696-704. 2009
    ..Our findings provide insight into the regulation of ERBB-2 expression in cancer and suggest that miR-331-3p has the capacity to regulate signaling pathways critical to the development and progression of prostate cancer cells...
  70. pmc Matriptase is involved in ErbB-2-induced prostate cancer cell invasion
    Shang Ru Wu
    Department of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, R817, 8F, No 1, Section 1, Jen Ai Rd, Taipei, Taiwan
    Am J Pathol 177:3145-58. 2010
    ..In summary, our data indicate that ErbB-2 signaling via the phosphatidylinositol 3-kinase pathway results in up-regulated matriptase zymogen activity, which contributes to PCa cell invasion...
  71. pmc Neuregulin-1-human epidermal receptor-2 signaling is a central regulator of pulmonary epithelial permeability and acute lung injury
    James H Finigan
    Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio 44106, USA
    J Biol Chem 286:10660-70. 2011
    ..We hypothesized that the tyrosine kinase receptor human epidermal growth factor receptor-2 (HER2) would be activated in an inflammatory setting and participate in ALI...
  72. doi Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples
    Benedict Yan
    Department of Pathology, National University Health System and National University of Singapore, Singapore
    J Clin Pathol 64:880-3. 2011
    Determination of HER2 protein expression by immunohistochemistry (IHC) and genomic status by fluorescent in situ hybridisation (FISH) are important in identifying a subset of high HER2-expressing gastric cancers that might respond to ..
  73. doi ErbB2 down-regulates microRNA-205 in breast cancer
    Ryohei Adachi
    Department of Public Health, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Japan
    Biochem Biophys Res Commun 411:804-8. 2011
    Gene amplification and protein overexpression of erbB2 (Her2/neu) has been observed in approximately 20-30% of breast cancers...
  74. doi The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination
    Lydia M Balz
    Institute of Immunology, Witten Herdecke University, Germany
    J Pathol 227:234-44. 2012
    b>HER2 signalling by heterodimerisation with EGFR and HER3 in breast cancer is associated with worst outcome of the afflicted patients, which is attributed not only to the aggressiveness of such tumours but also to therapy resistance...
  75. ncbi HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses
    Rohit Bhargava
    Department of Pathology, Memorial Sloan Kettering, Cancer Center, New York, NY 10021, USA
    Am J Clin Pathol 123:889-95. 2005
    We studied HER-2/neu (HER-2) and topoisomerase IIa (topo2a) amplification (using chromogenic in situ hybridization) and overexpression (immunohistochemical analysis) in 113 invasive breast carcinomas...
  76. doi Aberrations of ERBB2 and TOP2A genes in breast cancer
    Kirsten Vang Nielsen
    Dako A S, Glostrup, Denmark
    Mol Oncol 4:161-8. 2010
    Copy number changes in TOP2A have frequently been linked to ERBB2 (HER2) amplified breast cancers...
  77. doi Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients
    Marta Pestrin
    Translational Research Unit c o Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Piazza dell Ospedale 2, 59100, Prato, Italy
    Breast Cancer Res Treat 118:523-30. 2009
    ..We assessed HER2 status on CTCs from blood samples of ABC patients. CTCs were separated and stained using the CellSearch System((R))...
  78. doi Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome
    Isabell D Witzel
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    J Cancer Res Clin Oncol 136:1709-18. 2010
    ..enter clinical practice, simultaneous determination of currently established markers like human epidermal growth factor receptor 2 (HER2), urokinase plasminogen activator (uPA) and its inhibitor (PAI-1) would represent an ..
  79. ncbi Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells
    Janice M Knowlden
    Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Cardiff CF10 3XF, United Kingdom
    Endocrinology 144:1032-44. 2003
    ..These results demonstrate that TAM-R MCF-7 cell growth is mediated by the autocrine release and action of an EGFR-specific ligand inducing preferential EGFR/c-erbB2 dimerization and downstream activation of the ERK pathway...
  80. ncbi Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells
    Sarah Yoon
    Department of Biochemistry and Molecular Biology, Brain Korea 21 Project for Medical Science, Institute of Genetic Science, Center for Chronic Metabolic Disease Research, Seoul, Korea
    J Biol Chem 282:26122-31. 2007
    Expression of the HER2 oncogene is increased in approximately 30% of human breast carcinomas and is closely correlated with the expression of fatty acid synthase (FASN)...
  81. doi HER2 overexpression correlates with survival after curative resection of pancreatic cancer
    Masahiro Komoto
    Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan
    Cancer Sci 100:1243-7. 2009
    b>HER2 overexpression has been linked to clinical outcomes in several solid tumors, such as breast cancer. However, the correlation between HER2 overexpression and survival in pancreatic carcinoma remains unclear...
  82. doi Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification
    Junko Tanizaki
    Department of Medical Oncology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka, Japan
    Mol Cancer Ther 9:1198-207. 2010
    Amplification of human epidermal growth factor receptor 2 (HER2) has been detected in 20% to 30% of gastric cancers and is associated with a poor outcome...
  83. pmc Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
    Joan T Garrett
    Department of Medicine, Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, and Vanderbilt University Institute of Imaging Sciences, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Proc Natl Acad Sci U S A 108:5021-6. 2011
    ..of HER3 and its output to PI3K/Akt are required for the optimal antitumor effect of therapeutic inhibitors of the HER2 oncogene...
  84. doi HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data
    Angelo Di Leo
    Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Lancet Oncol 12:1134-42. 2011
    ..We aimed to assess the value of HER2 and TOP2A as predictive markers of response to anthracycline-based adjuvant therapy in patients with early breast ..
  85. ncbi HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors
    Elizabeth Half
    Department of Gastrointestinal Medicine and Nutrition University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Cancer 108:540-8. 2004
    The HER-2/neu oncogene encodes a 185 kD protein that is phosphorylated upon ligand binding to other HER/erbB members and regulates cell growth and differentiation...
  86. doi Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells
    Chien Chih Ou
    Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan 114, Republic of China
    Carcinogenesis 29:299-306. 2008
    Interferon-gamma (IFN-gamma) is known to downregulate HER2 oncoprotein (p185(HER2) or briefly p185) in prostate cancer cells. We demonstrate that the IFN-gamma-induced retinoid-inducible gene 1 (RIG1) acts as a transrepressor of p185...
  87. doi Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells
    Kwang Kyu Kim
    Molecular Cancer Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea
    Carcinogenesis 29:704-12. 2008
    ..Collectively, these results show that MIC-1 may participate in the malignant progression of certain human cancer cells that overexpress ErbB2 through the transactivation of ErbB2 tyrosine kinase...
  88. doi The WW domain containing E3 ubiquitin protein ligase 1 upregulates ErbB2 and EGFR through RING finger protein 11
    C Chen
    The Center for Cell Biology and Cancer Research, MS355, Albany Medical College, Albany, NY 12208, USA
    Oncogene 27:6845-55. 2008
    ..These findings suggest that WWP1 may promote cell proliferation and survival partially through suppressing RNF11-mediated ErbB2 and EGFR downregulation...
  89. pmc Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study
    A K Koutras
    Division of Oncology, Department of Medicine, University Hospital of Patras, Rion, Greece
    Br J Cancer 99:1775-85. 2008
    ..profiling of the HER family genes in early breast cancer, as well as to investigate the predictive value of HER2 mRNA expression for adjuvant treatment with paclitaxel...
  90. pmc Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry
    Yukie Sato-Kuwabara
    Department of Anatomic Pathology, Hospital AC Camargo, Sao Paulo, SP, Brazil
    BMC Cancer 9:6. 2009
    ..implications; however, few studies involving fluorescence in situ hybridization (FISH) analysis of HER-2/neu gene amplification and protein expression in ESCC have been conducted...
  91. doi Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients
    Alexandra F Leary
    Royal Marsden Hospital, London, UK
    J Clin Oncol 27:1694-705. 2009
    ..This conclusion is in agreement with the 2007 American Society of Clinical Oncology guidelines on the use of biomarkers in breast cancer...
  92. pmc Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy
    F P O'Malley
    Sunnybrook Odette Cancer Centre, University of Toronto, 2075 Bayview Ave, Toronto, Ontario, Canada
    J Natl Cancer Inst 101:644-50. 2009
    ..II alpha (TOP2A) gene in breast cancers has been postulated to be more closely associated with responsiveness to anthracycline-containing chemotherapy than amplification of the human epidermal growth factor receptor type 2 (HER2) gene.
  93. doi ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor
    C Osipo
    Department of Pathology, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL 60153, USA
    Oncogene 27:5019-32. 2008
    ..EGFR)/ErbB-2 tyrosine kinase inhibitor (TKI) increased Notch activity by 2- to 6-fold in SKBr3, BT474 and MCF-7/HER2-18 cells...
  94. doi ADAM 10 is associated with gastric cancer progression and prognosis of patients
    Yuan Yu Wang
    Wenzhou Medical College, Wenzhou, Zhejiang, PR China
    J Surg Oncol 103:116-23. 2011
    ..The metalloproteinase domain-containing protein 10 (ADAM 10) has been implicated in the development and progression of gastric cancer...
  95. ncbi HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells
    Musaffe Tuna
    Department of Experimental Therapeutics, Unit 422, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, USA
    Oncogene 24:1648-52. 2005
    ..Here we report that the HER2/neu oncogene increases WT1 expression...
  96. pmc The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane
    Camilla Haslekås
    Institute of Pathology, University of Oslo, Rikshospitalet, 0027 Oslo, Norway
    Mol Biol Cell 16:5832-42. 2005
    ....
  97. pmc Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation
    Xiangdong Zhou
    Department of Biochemistry and The Marry Babb Randolph Cancer Center, West Virginia University, Morgantown, West Virginia 26506, USA
    J Biol Chem 284:12226-34. 2009
    The Src homology phosphotyrosyl phosphatase 2 (SHP2) plays a positive role in HER2-induced signaling and transformation, but its mechanism of action is poorly understood...
  98. pmc Expression profiling during mammary epithelial cell three-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2-mediated transformation
    Min Yu
    Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA
    Mol Cell Biol 32:3913-24. 2012
    ..Furthermore, we showed that the receptor tyrosine kinase ErbB2/HER2 is a direct substrate of PTPRO and that loss of PTPRO increased ErbB2-induced cell proliferation and transformation,..
  99. ncbi Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas
    M Alimandi
    Laboratory of Cellular and Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Oncogene 10:1813-21. 1995
    ....
  100. ncbi Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells
    G Brockhoff
    Institute of Pathology, University Regensburg, Regensberg, Germany
    Cytometry 44:338-48. 2001
    ..We investigated the recruitment of receptor complexes in two c-erbB2-overexpressing breast carcinoma cell lines, SK-BR-3 and BT474, after ligand binding and its effects on intracellular signal transduction and cell cycle regulation...
  101. ncbi Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu
    Joanna Jasinska
    BioLife Science GmbH, Vienna, Austria
    Int J Cancer 107:976-83. 2003
    ..Moreover, peptide immunization in rabbits generated anti-Her 2-neu IgG that, in contrast to mouse sera, were able to mediate a 31-46% lysis of SK-BR-3 cells in ADCC experiments...

Research Grants70

  1. ERBB2 RECEPTOR SIGNALING AND BREAST CANCER METASTASIS
    Dihua Yu; Fiscal Year: 2002
    ..The previous work have demonstrated that activated c-erbB-2/neu (also known as HER-2) oncogene can lead to higher metastatic potential in mouse 3T3 cells...
  2. Mouse Models of ErbB-2 and Cyclin D1 in Prostate Cancer
    Christopher Albanese; Fiscal Year: 2002
    ..abstract_text> ..
  3. Coexpression of EGFRvlll/ErbB2 in Human Breast Cancer
    Careen Tang; Fiscal Year: 2005
    ..despite the encouraging results from the advanced-disease trials with an anti-ErbB-2 antibody, Herceptin (rhuMAb HER2 or trastuzumab) clearly does not cure all tumors that overexpress ErbB-2...
  4. REBECCA SARA COOK; Fiscal Year: 2014
    DESCRIPTION (provided by applicant): The ErbB family of receptor tyrosine kinases includes EGFR, ErbB2/HER2, ErbB3/HER3 and ErbB4/HER4. Abundant evidence supports the causal role of HER2 overexpression in up to 25% of all breast cancers...
  5. A novel biotherapeutic for triple-negative breast cancer.
    Randolph C Elble; Fiscal Year: 2010
    ..of estrogen and growth factor receptors that have driven the increase in overall survival of patients with ER+ and HER2+ breast cancers...
  6. Theranostic Nanomedicine for Breast Cancer Prevention and Image-Guided Therapy
    Prakash R Rai; Fiscal Year: 2011
    ..PDT) for localized cytotoxicity and simultaneous biological therapy to improve the treatment outcomes against HER2 positive and triple negative BrCa...
  7. Prakash R Rai; Fiscal Year: 2014
    ..PDT) for localized cytotoxicity and simultaneous biological therapy to improve the treatment outcomes against HER2 positive and triple negative BrCa...
  8. Jia Luo; Fiscal Year: 2016
    ..We will investigate the effect of ethanol on mammary tumorigenesis/metastasis in MMTV-Neu transgenic mice...
  9. Lali K Medina-Kauwe; Fiscal Year: 2016
    ..To test the feasibility of this new type of therapeutic, we have chosen HER2+ breast cancer as our tumor target...
  10. Dai Horiuchi; Fiscal Year: 2014
    ..TN) breast cancer, the most difficult-to-treat form of breast cancer, which does not overexpress human epidermal growth factor receptor 2 (HER2) and lacks the expression of the estrogen and progesterone receptors...
  11. Aptamer-siRNA Chimeras Targeting HER2-Positive Breast Cancers
    PALOMA HOBAN GIANGRANDE; Fiscal Year: 2013
    ..that one out of 4 breast cancers exhibits elevated levels of the epidermal growth factor receptor type 2 (HER2) is one of the most significant recent discoveries in breast cancer research...
  12. Novel Mechanisms of EGFR Gene Expression Regulation
    Marianela Perez Torres; Fiscal Year: 2010
    ..A full understanding of the regulators of EGFR expression is needed to design sound therapeutic approaches for patients with EGFR over expressing tumors. ..
  13. Developing miRNA diagnostic methods and identifying tumor regulatory networks
    Thomas Tuschl; Fiscal Year: 2010
    ..last aim, we will apply our methods to assess the value of miRNA analysis in a large collection of triple negative (HER2 gene amplification, Estrogen Receptor (ER), and Progesterone Receptor (PR) negative) and other types of breast ..
  14. Validation of the Estrogen Related Receptor as a therapeutic target in cancer
    Donald P McDonnell; Fiscal Year: 2012
    ..e. HER2 signaling)...
  15. Jaime L Matta; Fiscal Year: 2016
    ..We hypothesize that BC patients with HER2/neu or progesterone receptors are more likely to have a low DRC than patients with estrogen receptors...
  16. Susan L Deutscher; Fiscal Year: 2016
    ..This work is significant and relevant to the VA mission because the peptides discovered here may translate into novel prostate, breast, and ovarian cancer diagnostics and therapeutics for our veterans. ..
  17. Peptide-targeted alpha-particle emitting phage for ovarian cancer therapy.
    Thomas P Quinn; Fiscal Year: 2013
    ....
  18. BIOMEDICAL (BASIC)
    RICHARD TESTA; Fiscal Year: 2009
    ..These studies will form the foundation for Phase II studies aimed at developing Pb-based alpha-particle emitting ErbB-2-targeting peptides for the treatment of ovary, lung, and breast cancers. ..
  19. Low-Cost Digital Gene Expression System
    STEVEN JEFFREY GORDON; Fiscal Year: 2013
    ....
  20. Roles of NF-kB/Rel in the pathogenesis of breast cancer
    Gail E Sonenshein; Fiscal Year: 2012
    ..Importantly, mutant Ras and Her-2/neu overexpression, which can be induced by DMBA exposure, were found to activate NF-?B...
  21. Henry J Thompson; Fiscal Year: 2016
    ..identifying subcategories of tumors (initially categorized by estrogen and progesterone receptor status and Her-2/Neu expression) that regress in response to PA;mechanisms that account for regression will be identified...
  22. PROGESTIN AND GROWTH FACTOR CROSS-TALK IN BREAST CANCER
    CAROL ANN LANGE; Fiscal Year: 2010
    ..This work will aid our understanding of steroid hormone action, and help to identify and implicate new therapeutic targets for breast cancer prevention and treatment. ..
  23. MicroRNA Signature of Tamoxifen Resistance in Breast Cancer
    Sarmila Majumder; Fiscal Year: 2010
    ..This observation was also validated in Her2/neu positive primary human breast tumors that respond poorly to endocrine therapy...
  24. INTEGRIN FUNCTION AND SIGNALING IN CARCINOMA PROGRESSION
    Arthur M Mercurio; Fiscal Year: 2012
    ..tumors, aggressive tumors that retain features of basal epithelial cells and lack expression of ER, PR and HER2 ([unreadable]triple negative[unreadable])...
  25. Li Xin Wang; Fiscal Year: 2015
    ..We will use neu-N transgenic mice which express the oncogene rat HER-2/neu specifically in breast tissue...
  26. Breast cancer prevention with Nexrutine
    SUSAN PATRICIA LANZA-JACOBYY; Fiscal Year: 2012
    ..of this study, we found that Nexrutine reduced excessive branching of mammary gland terminal end buds from HER-2/neu transgenic mice and decreased PGE2 production in the mammary glands...
  27. CATHY A SWINDLEHURST; Fiscal Year: 2014
    ..for a first-in- class small molecule therapeutic for triple negative (estrogen receptor, progesterone receptor, and HER2 negative) breast cancer with an emphasis on reducing recurrence and increasing survival rates...
  28. Paul Dent; Fiscal Year: 2014
    ..We will grow rodent mammary carcinoma MMTV-HER2 cells and 4T1in the mammary fat pad of immune competent syngeneic FVB/NJ and BALB/c mice, respectively;for 4T1 ..
  29. Julie R Palmer; Fiscal Year: 2015
    ..By pooling our data, specimens, and importantly, expertise to investigate these synergist hypotheses, we will elucidate much of the etiology of aggressive, early onset breast cancers in AA women. ..
  30. Mechanisms of tumor resistance to anti-HER/ErbB therapeutics
    Zhen Fan; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Trastuzumab (Herceptin), a humanized anti-HER2 monoclonal antibody, has been demonstrated to confer a clear survival benefit when it is added to standard chemotherapy for HER2-overexpressing breast ..
  31. Thomas E Yankeelov; Fiscal Year: 2016
    ..degree of tumor response after one and two cycles of Carboplatin and nab-Paclitaxel with or without Vorinostat in HER2-negative primary operable breast cancer. 3...
  32. Said M Sebti; Fiscal Year: 2014
    ..Clinical trials will be performed to evaluate the efficacy of the drug combinations. ..
  33. Heregulin signaling via small GTPases in mitogenesis and tumorigenesis
    MARCELO GABRIEL KAZANIETZ; Fiscal Year: 2010
    ..The goal is to determine the implications of this pathway in breast cancer using cellular and animal models, and to elucidate molecular mechanisms by which HRG signals to Rac via P-Rex1. ..
  34. Ignat Printsev; Fiscal Year: 2015
    ..Furthermore, courses related to the project would aid in the development of perspectives and strategies important to the progression of the technical and theoretical facets of the research...
  35. The Role of Syndecan-1 in Mouse Mammary Neoplasia
    CAROLINE MARGARET ALEXANDER; Fiscal Year: 2012
    ..that have a significantly worse prognosis than the others, the so-called triple negative tumors (ER-ve, PR-ve, HER2-)...
  36. Immunotherapeutic strategies for breast cancer
    YVONNE J PATERSON; Fiscal Year: 2010
    We propose to develop Listeria monocytogenes, as a cancer therapeutic for HER-2/neu expressing breast tumors. We have shown that recombinant L...
  37. Optimization of compounds that selectively inhibit protein synthesis for the trea
    CATHY A SWINDLEHURST; Fiscal Year: 2010
    ..translation initiation for the treatment of triple negative (estrogen receptor, progesterone receptor, and HER2 negative) breast tumors with an emphasis on reducing recurrence and increasing survival rates...
  38. ALBERT SIDNEY BALDWIN; Fiscal Year: 2014
    ..ER-negative cancer comprises at least two distinct subtypes: the Her2+ subtype and the basal-like subtype...
  39. David D Tran; Fiscal Year: 2016
    ..These 3 aims will allow us to critically address a role for Twist1 in EMT maintenance and tumor dormancy. The result will hopefully provide new targets to control tumor dormancy and stimulate research into this significant problem. ..
  40. Michele I Vitolo; Fiscal Year: 2016
    ..tumor cell dormancy, and metastatic outgrowth due to PTEN loss in combination with the known oncogene ErbB2 (Her2/Neu)...
  41. Ann Marie Pendergast; Fiscal Year: 2015
    ..found that endogenous Abl kinases are hyperactivated in a subset of breast cancer cell lines that are negative for Her2 and hormone receptors...
  42. Development of inhibitors targeting the TGF-beta-NfkB axis in cancer
    Andrei Bakin; Fiscal Year: 2013
    ..axis in cancer, activating molecular pathways contributing to aggressive breast cancers, such as ER-negative and HER2-positive cancers, that are difficult to treat with present therapies...
  43. Investigation of the Role of NF-??B in Breast Cancer Tumor Initiating Cells
    Megan F Kendellen; Fiscal Year: 2010
    ..the TIC phenotype in primary human breast tumor samples, human breast cancer cell lines, and murine models of human HER2+ and basal breast cancer...
  44. Nicholas Navin; Fiscal Year: 2016
    ..application is to use single cell-sequencing to delineate the clonal substructure of triple-negative (ER-, PR-, Her2-) breast tumors and infer genomic evolution at different stages of primary tumor growth...
  45. Biological Breast Cancer Classification by qRT-PCR
    Matthew Ellis; Fiscal Year: 2009
    ..identified five distinct subtypes of breast tumors: Luminal A (LumA), Luminal B (LumB), Normal Breast-like (NB), HER2-positive (HER2+) and Basal-like...
  46. Mechanisms of Src activation and its role in latent bone metastasis of breast and
    Xiang H F Zhang; Fiscal Year: 2013
    ..We are therefore going to extend the original aim (Aim 1) by corroborating and generalizing this model. ..
  47. Stochastic Control of Abnormal Morphogenesis Induced by the ErbB2 Oncoprotein
    Kevin Janes; Fiscal Year: 2009
    ..Such genes could link ErbB2 to drug sensitivity, providing new avenues for more-effective anti-cancer therapeutics. ..
  48. Yosef Yarden; Fiscal Year: 2014
    The EGFR/HER2 signaling network emerges as an effective therapeutic target in lung, colon, pancreas, head/neck and breast tumors...
  49. Kermit L Carraway; Fiscal Year: 2016
    ..Overall, these studies will validate Muc4 as a novel contributor to breast cancer progression, and will begin to unravel biochemical pathways that might ultimately be exploited for therapeutic intervention. ..
  50. JAMES OLIVER MCINTYRE; Fiscal Year: 2015
    ..The paradigm we have chosen to achieve these ends considers two major categories of human breast cancer, HER2 positive tumors and ER/PR/HER2 triple-negative tumors and both established and emerging therapies...
  51. Thomas E Yankeelov; Fiscal Year: 2016
    ..To achieve this goal, we will pursue the following specific aims: 1. (Pre-clinical validation) In the BT-474 HER2+ human breast cancer cell line, we will obtain: 1a...
  52. Oncogenic role of PIK3CA hotspot mutations
    RAMON E PARSONS; Fiscal Year: 2013
    ..Genetic relationships with the downstream oncogene Akt1 and the candidate collaborating partners PTEN, HER2/Erbb2 and IGF1R will then be investigated...
  53. Genistien and prevention of HER2-overexpressing breast *
    Jin Rong Zhou; Fiscal Year: 2005
    ..is focused on the effects soy phytochemicals on preventing the progression of estrogen receptor-positive [ER(+)]and HER2-overexpressing breast cancer (BRCA)...
  54. Evaluation of In Vitro Companion Diagnostic Monoclonal Antibodies for Use in a St
    Christopher Horvath; Fiscal Year: 2013
    ..cells (TVECs), tumor cells (TCs) and cancer stem cells (CSCs) in "triple-negative" (TNBC;estrogen, progesterone and Her2 receptor-negative) breast cancer (BCa), pancreatic adenocarcinoma (PCa) and glioblastoma multiforme (GBM) primary ..
  55. Structural Studies of Growth Factor Receptor Function
    Daniel J Leahy; Fiscal Year: 2010
    ..For example, overexpression of the EGF receptor homologue ErbB2/HER2 is found in 20-25% of human breast cancers and is associated with more aggressive tumors and a poorer prognosis...
  56. Chimeric IgG/A Tumor Immunotherapy
    KEITH WYCOFF; Fiscal Year: 2013
    ..As proof of concept we will link the Fab domains of an anti-HER2 antibody to a fusion of the Fc ?1 CH1-CH2-CH3 domains and Fc ?2 CH2-CH3 domains...
  57. Stephen W Byers; Fiscal Year: 2015
    ..of the six breast cancer subtypes, and include those that are 'triple negative'(lacking ER-alpha, PR and HER2 expression), denoting clinically poor prognosis with few treatment options...
  58. Susanta K Sarkar; Fiscal Year: 2015
    ..In a study of HER2-negative metastatic breast cancer a combination of paclitaxel with an anti-VEGF humanized antibody, bevacizumab, ..
  59. Neutrophil and complement attracting anti-cancer monoclonal antibody conjugates:
    Ifat Rubin-Bejerano; Fiscal Year: 2013
    ..Herceptin (trastuzumab) is a mAb used to treat breast cancer patients whose tumors display the HER2 molecule...
  60. Therapeutic antibody to radiation inducible TIP1 activates immune effector cells
    Marshall Michener; Fiscal Year: 2012
    ..g. 30% breast cancers express Her2/neu)...
  61. Structure/function studies of nucleoside analog activating enzymes
    Arnon Lavie; Fiscal Year: 2009
    ..Moreover, the modular nature of the conjugate means that diverse cancers could be treated (e.g. HER2+ breast cancer, CD33+ leukemias, PSMA+ prostate cancer), by simply conjugating the appropriate mAb to dCKEN
  62. Enzyme-delivery scaffold technology for targeted cancer killing.
    Arnon Lavie; Fiscal Year: 2013
    ..We will test the efficiency and selectivity of the delivery scaffolds for their ability to ferry dCKEN into HER2 positive cells...
  63. Adaptive Immunity from High Affinity Anti-HER2/neu Monoclonal Antibodies
    Louis M Weiner; Fiscal Year: 2010
    ..To test these hypotheses, the C6.5 series of anti-human HER2/neu single-chain Fv molecules (scFv) has been converted into fully human lgG1 molecules that identify an identical ..
  64. Genetic variation and regulatory networks: Mechanisms and complexity
    DANA PE ER; Fiscal Year: 2009
    ..These tools will be made publicly available, including a friendly graphical user interface and visualization. ..
  65. Personalized Clinical Diagnostics and Beyond: Integrated Ring Resonator Arrays
    Ryan Bailey; Fiscal Year: 2009
    ..This technology promises to broadly impact the landscape of the biomedical sciences, both meeting the clinical diagnostic challenges of today and pioneering the paradigm-shifting discoveries of tomorrow. ..
  66. PATHOBIOLOGY OF BREAST CANCER AND HORMONE RECEPTORS
    Michael Press; Fiscal Year: 2003
    ..Considerable evidence indicates that another receptor, HER-2/neu, is equally important in breast cancer specimens...
  67. HER-2 NEU PROTO-ONCOGENE IN OVARIAN & ENDOMETRIAL CANCER
    Michael Press; Fiscal Year: 1993
    ..Our preliminary results show that the HER-2/neu proto-oncogene is amplified and overexpressed in human ovarian cancer and in endometrial cancer...
  68. Standardization of HER-2/neu Tests
    Junqi Qian; Fiscal Year: 2001
    ..The detection, diagnosis, and treatment of this cancer is a major initiative in the United States. HER-2/neu overexpression is associated with breast cancer prognosis and response to chemotherapy or endocrine therapy...
  69. Prognostic and predictive gene sets in HER2-positive breast cancer:The HERA Trial
    Brian Leyland Jones; Fiscal Year: 2010
    ..cancer, based on combined expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), have important implications in breast cancer etiology, systemic therapies prescribed, ..
  70. HER2 Pathway in Breast Cancer Progression and Treatment
    Rakesh Kumar; Fiscal Year: 2007
    Overexpression of the human epidermal growth factor receptor 2 (HER2) gene product frequently associate with an aggressive clinical course, decreased disease-free survival, poor prognosis, and increased resistant and metastasis in human ..